Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials (2023)
Attributed to:
nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/cei/uxad013
Publication URI: http://dx.doi.org/10.1093/cei/uxad013
Type: Journal Article/Review
Parent Publication: Clinical and Experimental Immunology
Issue: 3